SEARCH

SEARCH BY CITATION

References

  • Aggelidou E, Hillhouse EW, Grammatopoulos DK (2002). Up-regulation of nitric oxide synthase and modulation of the guanylate cyclase activity by corticotropin-releasing hormone but not urocortin II or urocortin III in cultured human pregnant myometrial cells. Proc Natl Acad Sci USA 99: 33003305.
  • Assil IQ, Qi LJ, Arai M, Shomali M, Abou-Samra AB (2001). Juxtamembrane region of the amino terminus of the corticotropin releasing factor receptor type 1 is important for ligand interaction. Biochemistry 40: 11871195.
  • Audsley N, Kay I, Hayes TK, Coast GM (1995). Cross reactivity studies of CRF-related peptides on insect Malpighian tubules. Comp Biochem Physiol A Physiol 110: 8793.
  • Bale TL, Vale WW (2004). CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44: 525557.
  • Bangasser DA, Curtis A, Reyes BA, Bethea TT, Parastatidis I, Ischiropoulos H et al. (2010). Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology. Mol Psychiatry 15: 896904.
  • Berger H, Heinrich N, Wietfeld D, Bienert M, Beyermann M (2006). Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain. Br J Pharmacol 149: 942947.
  • Beyermann M, Heinrich N, Fechner K, Furkert J, Zhang W, Kraetke O et al. (2007). Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain. Br J Pharmacol 151: 851859.
  • Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH et al. (2004a). Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 145: 2435.
  • Brar BK, Chen A, Perrin MH, Vale W (2004b). Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Endocrinology 145: 17181729.
  • Cantarella G, Lempereur L, Lombardo G, Chiarenza A, Pafumi C, Zappala G et al. (2001). Divergent effects of corticotropin releasing hormone on endothelial cell nitric oxide synthase are associated with different expression of CRH type 1 and 2 receptors. Br J Pharmacol 134: 837844.
  • Chang CL, Hsu SY (2004). Ancient evolution of stress-regulating peptides in vertebrates. Peptides 25: 16811688.
  • Chen AM, Perrin MH, Digruccio MR, Vaughan JM, Brar BK, Arias CM et al. (2005). A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. Proc Natl Acad Sci USA 102: 26202625.
  • Chen R, Lewis KA, Perrin MH, Vale WW (1993). Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA 90: 89678971.
  • Dautzenberg FM, Wille S, Braun S, Hauger RL (2002). GRK3 regulation during CRF- and urocortin-induced CRF1 receptor desensitization. Biochem Biophys Res Commun 298: 303308.
  • Denver RJ (1997). Environmental stress as a developmental cue: corticotropin-releasing hormone is a proximate mediator of adaptive phenotypic plasticity in amphibian metamorphosis. Horm Behav 31: 169179.
  • Dermitzaki E, Tsatsanis C, Gravanis A, Margioris AN (2002). Corticotropin-releasing hormone (CRH) induces Fas ligand production and apoptosis in PC12 cells via activation of p38 MAPK. J Biol Chem 277: 1228012287.
  • Elliott-Hunt CR, Kazlauskaite J, Wilde GJC, Grammatopoulos D, Hillhouse EW (2002). Potential signalling pathways underlying corticotropin-releasing hormone's mediated neuroprotection from excitotoxicity in rat hippocampus. J Neurochem 80: 416425.
  • Facci L, Stevens DA, Pangallo M, Franceschini D, Skaper SD, Strijbos PJ (2003). Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors. Neuropharmacology 45: 623636.
  • Gkountelias K, Tselios T, Venihaki M, Deraos G, Lazaridis I, Rassouli O et al. (2009). Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding. Mol Pharmacol 75: 793800.
  • Grace CR, Perrin MH, DiGruccio MR, Miller CL, Rivier JE, Vale WW et al. (2004). NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proc Natl Acad Sci USA 101: 1283612841.
  • Grace CR, Perrin MH, Gulyas J, Digruccio MR, Cantle JP, Rivier JE et al. (2007). Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand. Proc Natl Acad Sci USA 104: 48584863.
  • Grace CR, Perrin MH, Gulyas J, Rivier JE, Vale WW, Riek R (2010). NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist. J Biol Chem 285: 3858038589.
  • Grammatopoulos D, Hillhouse EW (1999). Activation of protein kinase C by oxytocin inhibits the biological activity of the human myometrial CRH receptor at term. Endocrinology 140: 585594.
  • Grammatopoulos DK, Dai Y, Randeva HS, Levine MA, Karteris E, Easton AJ et al. (1999). A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes. Mol Endocrinol 13: 21892202.
  • Grammatopoulos DK, Randeva HS, Levine MA, Katsanou ES, Hillhouse EW (2000). Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins. Mol Endocrinol 14: 20762091.
  • Grammatopoulos DK, Randeva HS, Levine MA, Kanellopoulou KA, Hillhouse EW (2001). Rat cerebral cortex corticotropin-releasing hormone receptors: evidence for receptor coupling to multiple G-proteins. J Neurochem 76: 509519.
  • Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G et al. (2002). CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 143: 807813.
  • Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G et al. (2007). Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol 264: 4449.
  • Haug T, Storm JF (2000). Protein kinase A mediates the modulation of the slow Ca(2+)-dependent K(+) current, I(sAHP), by the neuropeptides CRF, VIP, and CGRP in hippocampal pyramidal neurons. J Neurophysiol 83: 20712079.
  • Hauger RL, Smith RD, Braun S, Dautzenberg FM, Catt KJ (2000). Rapid agonist-induced phosphorylation of the human CRF receptor, type 1: a potential mechanism for homologous desensitization. Biochem Biophys Res Commun 268: 572576.
  • Hauger RL, Olivares-Reyes JA, Braun S, Catt KJ, Dautzenberg FM (2003). Mediation of corticotropin releasing factor type 1 receptor phosphorylation and desensitization by protein kinase C: a possible role in stress adaptation. J Pharmacol Exp Ther 306: 794803.
  • Hillhouse EW, Grammatopoulos DK (2006). The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 27: 260286.
  • Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD et al. (2004). Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists. Biochemistry 43: 39964011.
  • Hoare SR, Sullivan SK, Fan J, Khongsaly K, Grigoriadis DE (2005). Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity. Peptides 26: 457470.
  • Hoare SR, Fleck BA, Gross RS, Crowe PD, Williams JP, Grigoriadis DE (2008). Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation. Mol Pharmacol 73: 13711380.
  • Holmes KD, Babwah AV, Dale LB, Poulter MO, Ferguson SS (2006). Differential regulation of corticotropin releasing factor 1alpha receptor endocytosis and trafficking by beta-arrestins and Rab GTPases. J Neurochem 96: 934949.
  • Hsu SY, Hsueh AJ (2001). Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7: 605611.
  • Huang M, Kempuraj D, Papadopoulou N, Kourelis T, Donelan J, Manola A et al. (2009). Urocortin induces interleukin-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF-kappaB activation. J Mol Endocrinol 42: 397405.
  • Jahn O, Tezval H, van Werven L, Eckart K, Spiess J (2004). Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity. Neuropharmacology 47: 233242.
  • Jin D, He P, You X, Zhu X, Dai L, He Q et al. (2007). Expression of corticotropin-releasing hormone receptor type 1 and type 2 in human pregnant myometrium. Reprod Sci 14: 568577.
  • Kageyama K, Hanada K, Moriyama T, Nigawara T, Sakihara S, Suda T (2006). G protein-coupled receptor kinase 2 involvement in desensitization of corticotropin-releasing factor (CRF) receptor type 1 by CRF in murine corticotrophs. Endocrinology 147: 441450.
  • Karalis KP, Venihaki M, Zhao J, van Vlerken LE, Chandras C (2004). NF-kappaB participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene. J Biol Chem 279: 1083710840.
  • Karteris E, Grammatopoulos D, Randeva H, Hillhouse EW (2000). Signal transduction characteristics of the corticotropin-releasing hormone receptors in the feto-placental unit. J Clin Endocrinol Metab 85: 19891996.
  • Karteris E, Vatish M, Hillhouse EW, Grammatopoulos DK (2005). Preeclampsia is associated with impaired regulation of the placental nitric oxide-cyclic guanosine monophosphate pathway by corticotropin-releasing hormone (CRH) and CRH-related peptides. J Clin Endocrinol Metab 90: 36803687.
  • Karteris E, Markovic D, Chen J, Hillhouse EW, Grammatopoulos DK (2010). Identification of a novel corticotropin-releasing hormone type 1beta-like receptor variant lacking exon 13 in human pregnant myometrium regulated by estradiol-17beta and progesterone. Endocrinology 151: 49594968.
  • Khattak MN, Buchfelder M, Kleindienst A, Schöfl C, Kremenevskaja N (2010). CRH and SRIF have opposite effects on the Wnt/β-catenin signalling pathway through PKA/GSK-3β in corticotroph pituitary cells. Cancer Invest 28: 797805.
  • Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Coso OA et al. (2002). Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol 16: 16381651.
  • Ladds G, Davis K, Hillhouse EW, Davey J (2003). Modified yeast cells to investigate the coupling of G protein-coupled receptors to specific G proteins. Mol Microbiol 47: 781792.
  • Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C et al. (2001). Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98: 75707555.
  • Lezoualc'h F, Engert S, Berning B, Behl C (2000). Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB. Mol Endocrinol 14: 147159.
  • Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, Maki RA (1997a). Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol 11: 20482053.
  • Liaw CW, Grigoriadis DE, Lovenberg TW, De Souza EB, Maki RA (1997b). Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach. Mol Endocrinol 11: 980985.
  • Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB et al. (1995). Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 92: 836840.
  • Markovic D, Grammatopoulos DK (2009). Focus on the splicing of secretin GPCRs transmembrane-domain 7. Trends Biochem Sci 34: 443452.
  • Markovic D, Papadopoulou N, Teli T, Randeva H, Levine MA, Hillhouse EW et al. (2006). Differential responses of corticotropin-releasing hormone receptor type 1 variants to protein kinase C phosphorylation. J Pharmacol Exp Ther 319: 10321042.
  • Markovic D, Lehnert H, Levine MA, Grammatopoulos DK (2008a). Structural determinants critical for localization and signaling within the seventh transmembrane domain of the type 1 corticotropin releasing hormone receptor: lessons from the receptor variant R1d. Mol Endocrinol 22: 25052519.
  • Markovic D, Punn A, Lehnert H, Grammatopoulos DK (2008b). Intracellular mechanisms regulating corticotropin-releasing hormone receptor-2beta endocytosis and interaction with extracellularly regulated kinase 1/2 and p38 mitogen-activated protein kinase signaling cascades. Mol Endocrinol 22: 689706.
  • Markovic D, Punn A, Lehnert H, Grammatopoulos DK (2011). Molecular determinants and feedback circuits regulating type 2 CRH receptor signal integration. Biochim Biophys Acta Mol Cell Res 1813: 896907.
  • Mazur AW, Wang F, Tcheiner M, Donnelly E, Isfort RJ (2004). Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides. J Med Chem 47: 34503454.
  • Nemoto T, Mano-Otagiri A, Shibasaki T (2005). Urocortin 2 induces tyrosine hydroxylase phosphorylation in PC12 cells. Biochem Biophys Res Commun 330: 821831.
  • Nielsen SM, Nielsen LZ, Hjorth SA, Perrin MH, Vale WW (2000). Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras. Proc Natl Acad Sci USA 97: 1027710281.
  • Nordstrom KJ, Lagerstrom MC, Waller LM, Fredriksson R, Schioth HB (2009). The secretin GPCRs descended from the family of adhesion GPCRs. Mol Biol Evol 26: 7184.
  • Oakley RH, Olivares-Reyes JA, Hudson CC, Flores-Vega F, Dautzenberg FM, Hauger RL (2007). Carboxyl-terminal and intracellular loop sites for CRF1 receptor phosphorylation and beta-arrestin-2 recruitment: a mechanism regulating stress and anxiety responses. Am J Physiol Regul Integr Comp Physiol 293: R209R222.
  • Pal K, Swaminathan K, Xu HE, Pioszak AA (2010). Structural basis for hormone recognition by the human CRFR2{alpha} G protein-coupled receptor. J Biol Chem 285: 4035140361.
  • Papadopoulou N, Chen J, Randeva H, Levine MA, Hillhouse EW, Grammatopoulos D (2004). Protein kinase A-induced negative regulation of the corticotropin-releasing hormone (CRH) R1α receptor-ERK signal transduction pathway: the critical role of Ser301 for signalling switch and selectivity. Mol Endocrinol 18: 624639.
  • Park HJ, Kim HJ, Lee JH, Lee JY, Cho BK, Kang JS et al. (2005). Corticotropin-releasing hormone (CRH) downregulates interleukin-18 expression in human HaCaT keratinocytes by activation of p38 mitogen-activated protein kinase (MAPK) pathway. J Invest Dermatol 124: 751755.
  • Pedersen WA, Wan R, Zhang P, Mattson MP (2002). Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I. J Neurosci 22: 404412.
  • Perrin MH, Sutton S, Bain DL, Berggren WT, Vale WW (1998). The first extracellular domain of corticotropin releasing factor-R1 contains major binding determinants for urocortin and astressin. Endocrinology 13: 566570.
  • Perry SJ, Junger S, Kohout TA, Hoare SRJ, Struthers RS, Grigoriadis DE et al. (2005). Distinct conformations of the corticotropin releasing factor type 1 receptor adopted following agonist and antagonist binding are differentially regulated. J Biol Chem 280: 1156011568.
  • Pierce KL, Luttrell LM, Lefkowitz RJ (2001). New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20: 15321539.
  • Pioszak AA, Parker NR, Suino-Powell K, Xu HE (2008). Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1. J Biol Chem 283: 3290032912.
  • Punn A, Levine MA, Grammatopoulos DK (2006). Identification of signaling molecules mediating corticotropin-releasing hormone-R1alpha-mitogen-activated protein kinase (MAPK) interactions: the critical role of phosphatidylinositol 3-kinase in regulating ERK1/2 but not p38 MAPK activation. Mol Endocrinol 20: 31793195.
  • Radulovic M, Hippel C, Spiess J (2003). Corticotropin-releasing factor (CRF) rapidly suppresses apoptosis by acting upstream of the activation of caspases. J Neurochem 84: 10741085.
  • Ralph JA, Zocco D, Bresnihan B, Fitzgerald O, McEvoy AN, Murphy EP (2007). A role for type 1alpha corticotropin-releasing hormone receptors in mediating local changes in chronically inflamed tissue. Am J Pathol 170: 11211133.
  • Rasmussen TN, Novak I, Nielsen SM (2004). Internalization of the human CRF receptor 1 is independent of classical phosphorylation sites and of beta-arrestin 1 recruitment. Eur J Biochem 271: 43664374.
  • Reisine T, Rougon G, Barbet J, Affolter HU (1985). Corticotropin-releasing factor-induced adrenocorticotropin hormone release and synthesis is blocked by incorporation of the inhibitor of cyclic AMP-dependent protein kinase into anterior pituitary tumor cells by liposomes. Proc Natl Acad Sci USA 82: 82618265.
  • Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA et al. (2001). Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98: 28432848.
  • Rivier J, Gulyas J, Kirby D, Low W, Perrin MH, Kunitake K et al. (2002). Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem 45: 47374747.
  • Ruhmann A, Bonk I, Lin CR, Rosenfeld MG, Spiess J (1998). Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci USA 95: 1526415269.
  • Sananbenesi F, Fischer A, Schrick C, Spiess J, Radulovic J (2003). Mitogen-activated protein kinase signaling in the hippocampus and its modulation by corticotropin-releasing factor receptor 2: a possible link between stress and fear memory. J Neurosci 23: 1143611443.
  • Shaywitz AJ, Greenberg ME (1999). CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68: 821861.
  • Suda T, Kageyama K, Sakihara S, Nigawara T (2004). Physiological roles of urocortins, human homologues of fish urotensin I, and their receptors. Peptides 25: 16891701.
  • Sydow S, Flaccus A, Fischer A, Spiess J (1999). The role of the fourth extracellular domain of the rat corticotropin-releasing factor receptor type 1 in ligand binding. Eur J Biochem 259: 5562.
  • Sztainberg Y, Kuperman Y, Issler O, Gil S, Vaughan J, Rivier J et al. (2009). A novel corticotropin-releasing factor receptor splice variant exhibits dominant negative activity: a putative link to stress-induced heart disease. FASEB J 23: 21862196.
  • Teli T, Markovic D, Levine MA, Hillhouse EW, Grammatopoulos DK (2005). Regulation of corticotropin-releasing hormone receptor type 1alpha signaling: structural determinants for G protein-coupled receptor kinase-mediated phosphorylation and agonist-mediated desensitization. Mol Endocrinol 19: 474490.
  • Teli T, Markovic D, Hewitt ME, Levine MA, Hillhouse EW, Grammatopoulos DK (2008). Structural domains determining signalling characteristics of the CRH-receptor type 1 variant R1beta and response to PKC phosphorylation. Cell Signal 20: 4049.
  • Ulisse S, Fabbri A, Dufau ML (1989). Corticotropin-releasing factor receptors and actions in rat Leydig cells. J Biol Chem 264: 21562163.
  • Van Kolen K, Dautzenberg FM, Verstraeten K, Royaux I, De Hoogt R, Gutknecht E et al. (2010). Corticotropin releasing factor-induced ERK phosphorylation in AtT20 cells occurs via a cAMP-dependent mechanism requiring EPAC2. Neuropharmacology 58: 135144.
  • Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S et al. (1995). Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378: 287292.
  • Wietfeld D, Heinrich N, Furkert J, Fechner K, Beyermann M, Bienert M et al. (2004). Regulation of the coupling to different G proteins of rat corticotropin-releasing factor receptor type 1 in human embryonic kidney 293 cells. J Biol Chem 279: 3838638394.
  • Wille S, Sydow S, Palchaudhuri MR, Spiess J, Dautzenberg FM (1999). Identification of amino acids in the N-terminal domain of corticotropin-releasing factor receptor 1 that are important determinants of high-affinity ligand binding. J Neurochem 72: 388395.
  • Wu SV, Yuan PQ, Wang L, Peng YL, Chen CY, Taché Y (2007). Identification and characterization of multiple corticotropin-releasing factor type 2 receptor isoforms in the rat esophagus. Endocrinology 148: 16751687.
  • Wu Y, Zhang R, Zhou C, Xu Y, Guan X, Hu J et al. (2009). Enhanced expression of vascular cell adhesion molecule-1 by corticotrophin-releasing hormone contributes to progression of atherosclerosis in LDL receptor-deficient mice. Atherosclerosis 203: 360370.
  • Xiong Y, Xie LY, Abou-Samra AB (1995). Signaling properties of mouse and human corticotropin-releasing factor (CRF) receptors: decreased coupling efficiency of human type II CRF receptor. Endocrinology 136: 18281834.
  • Zbytek B, Pfeffer LM, Slominski AT (2006). CRH inhibits NF-kappa B signaling in human melanocytes. Peptides 27: 32763283.
  • Zhao J, Karalis KP (2002). Regulation of nuclear factor-kappaB by corticotropin-releasing hormone in mouse thymocytes. Mol Endocrinol 16: 25612570.
  • Zmijewski MA, Slominski AT (2009a). CRF1 receptor splicing in epidermal keratinocytes: potential biological role and environmental regulations. J Cell Physiol 218: 593602.
  • Zmijewski MA, Slominski AT (2009b). Modulation of corticotropin releasing factor (CRF) signaling through receptor splicing in mouse pituitary cell line AtT-20–emerging role of soluble isoforms. J Physiol Pharmacol 60: 3946.